From the Research
Fatigue is a common side effect of GLP-1 receptor agonists, and managing it requires a multifaceted approach, including staying well-hydrated, maintaining adequate caloric intake, and considering adjustments to medication timing or dosage, as supported by the most recent study 1.
Key Considerations
- Fatigue typically occurs during the first few weeks of treatment with GLP-1 receptor agonists like semaglutide, liraglutide, tirzepatide, and dulaglutide, and often improves over time as the body adjusts to the medication.
- To manage GLP-1 agonist-related fatigue, patients should ensure they are staying well-hydrated with at least 2 liters of water daily, as these medications can cause dehydration.
- Maintaining adequate caloric intake despite reduced appetite is crucial, focusing on protein-rich foods and complex carbohydrates for sustained energy.
- Considering taking the medication before bedtime, if approved by the doctor, may help sleep through some side effects.
- Regular light exercise, such as walking, can paradoxically improve energy levels.
- Supplementing with electrolytes if experiencing significant fluid losses is also recommended.
Clinical Evidence
The most recent study 1 provides a comprehensive review of GLP-1 agonist therapy and associated complications, highlighting the importance of understanding the indications for GLP-1 agonist use and associated adverse events to assist emergency clinicians.
Management Strategies
- If fatigue persists beyond 4-6 weeks or becomes severe, consulting a healthcare provider is essential, as they may adjust the dosage, slow down the titration schedule, or evaluate for other causes like anemia or thyroid dysfunction.
- The fatigue occurs because GLP-1 agonists slow gastric emptying and can affect blood glucose levels, potentially leading to temporary energy fluctuations as the body adapts to new metabolic patterns.